Carvedilol

Generic Name: Carvedilol

Brand Names: Coreg

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₆N_₂O_₄

CAS Number: 72956-09-3

Unique Ingredient Identifier: 0K47UL67F2

Background: Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker. It is currently used to treat heart failure, left ventricular dysfunction, and hypertension. The dual action of carvedilol is advantageous in combination therapies as moderate doses of 2 drugs have a decreased incidence of adverse effects compared to high dose monotherapy in the treatment of moderate hypertension.

Carvedilol was granted FDA approval on 14 September 1995.

Indication: Carvedilol is indicated to treat mild to severe heart failure, left ventricular dysfunction after myocardial infarction with ventricular ejection fraction ≤40%, or hypertension.

Associated Conditions: Atrial Fibrillation, Chronic Stable Angina Pectoris, Hypertension, LVEF ≤40% Left ventricular dysfunction, NYHA Class I or II heart failure, Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV)

Clinical Trials

Doppler Ultrasound Hepatic Vein Waveform as a Non-invasive Tool in the Assessment of Severity of Portal Hypertension

Phase 3

Conditions: Portal Hypertension

Interventions: Drug: Carvedilol

First Posted Date: 2016-11-29

Last Posted Date: 2016-12-05

Lead Sponsor: Aga Khan University

Target Recruit Count: 50

Registration Number: NCT02975323

Locations: 🇵🇰
Aga Khan University,, Karachi, Sind, Pakistan

Effect of Carvedilol on Exercise Performance in Fontan Patients

Phase 4

Completed

Conditions: Single Ventricle
Fontan

Interventions: Drug: Carvedilol
Drug: Placebo

First Posted Date: 2016-10-27

Last Posted Date: 2021-01-22

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 26

Registration Number: NCT02946892

Locations: 🇺🇸
University of Texas Southwestern, Dallas, Texas, United States

Beta Adrenergic Receptor Blockade as a Novel Therapy for Patients With Adenocarcinoma of the Prostate

Phase 2

Conditions: Prostate Cancer

Interventions: Drug: Carvedilol

First Posted Date: 2016-10-25

Last Posted Date: 2021-02-21

Lead Sponsor: Montefiore Medical Center

Target Recruit Count: 22

Registration Number: NCT02944201

Locations: 🇺🇸
Montefiore Medical Center, Bronx, New York, United States

Early Precise Diagnosis and Intervention of CPT Based on a Noninvasive 3D-vHPS

Phase 4

Conditions: Cirrhosis
Portal Hypertension

Interventions: Device: 3D-vHPS
Drug: Carvedilol
Procedure: Routine endoscopic procedures

First Posted Date: 2016-10-06

Last Posted Date: 2020-02-25

Lead Sponsor: Changqing Yang

Target Recruit Count: 100

Registration Number: NCT02925975

Locations: 🇨🇳
Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai, China

Spironolactone on Fibrosis Progrssion-Portal Hypertension(FP-PH)in Cirrhosis

Phase 4

Completed

Conditions: Cirrhosis
Portal Hypertension

Interventions: Drug: Carvedilol
Drug: Spironolactone and carvedilol

First Posted Date: 2016-09-20

Last Posted Date: 2020-08-25

Lead Sponsor: Changqing Yang

Target Recruit Count: 96

Registration Number: NCT02907749

Locations: 🇨🇳
Shanghai Tongji Hospital, Tongji University, Shanghai, Shanghai, China

Oral Carvedilol in Escalating Doses in the Acute Treatment of Atrial Fibrillation

Phase 3

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: oral carvedilol

First Posted Date: 2016-07-14

Last Posted Date: 2016-07-14

Lead Sponsor: Andhra Medical College

Target Recruit Count: 30

Registration Number: NCT02832089

Effects of Beta-blockade on Platelet Aggregation in Acute Coronary Syndrome

Phase 4

Completed

Conditions: Acute Coronary Syndrome

Interventions: Drug: Carvedilol
Drug: Metoprolol

First Posted Date: 2016-06-22

Last Posted Date: 2022-03-31

Lead Sponsor: Federico II University

Target Recruit Count: 100

Registration Number: NCT02809820

Locations: 🇮🇹
Federico II University of Naples, Naples, Italy

Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors

Phase 2

Completed

Conditions: Malignant Solid Neoplasm
Hematopoietic and Lymphoid Cell Neoplasm

Interventions: Drug: Carvedilol
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Other: Pharmacogenomic Study
Other: Placebo Administration
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2016-03-23

Last Posted Date: 2025-04-23

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 196

Registration Number: NCT02717507

Locations: 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Phoenix Childrens Hospital, Phoenix, Arizona, United States

and more 88 locations